IntegraGen is developing a predictive test based on the biomarker miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR (epidermal growth factor receptor) monoclonal antibody therapy response in wild-type KRAS patients with metastatic colorectal cancer.
IntegraGen has developed a molecular signature which molecularly classifies tumors from patients with hepatocelluar carcinoma (HCC) based on the tumor's genetic makeup. This signature also identifies the prognosis and recurrence risk for patients with liver cancer.
IntegraGen is developing a molecular test based on the biomarker hsa-miR-31-3p, a microRNA whose expression has been correlated with the effect of EGFR TKIs (epidermal growth factor receptor tyrosine kinase inhibitors) in patients with advanced non-small cell lung cancer (NSCLC).
The Interpretation of Clinical Exome or ICE Project is a collaborative effort led by IntegraGen to develop an advanced scientific software program that will aid in the interpretation of genome sequencing data obtained from cancer patients.
IntegraGen is conducting groundbreaking research in the area of oncology biomarkers and the development of an advanced scientific software program that will aid in the interpretation of genome sequencing data obtained from cancer patients. Click here for the latest updates on our progress.